UnknownPhase 2, PHASE3

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy

Lead sponsor

Hadassah Medical Organization

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Estimated enrollment

Study population

Eligibility highlights

Primary endpoints

•Insulin levels in blood in response to Glucose Challenge - Oral Glucose•Platelet aggregation to Adenosine diphosphate (ADP)•Nerve conduction velocity in VEP

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02882477

Org study ID0003-16-HMO

Timeline

Milestones

Study first posted2016-08-29estimated

Last update posted2016-08-29estimated

Study start2016-12 (month precision)

Primary completion2018-05estimated (month precision)

Study completion2018-12estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who can enroll

Minimum age3 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female patients, of any age genetically and clinically diagnosed with Wolfram syndrome type 2.

Exclusion criteria

•Patients who are non-cooperative.

•Patients with bone marrow disease or neutropenia.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Other (unclassified)

Glycemic / diabetes

4 endpoints

Primary/protocol endpoint

Insulin levels in blood in response to Glucose Challenge - Oral Glucose tolerance test (OGTT ) and Intra venous glucose tolerance test (IVGTT)

Time frame:5 months

descriptive

Primary/protocol endpoint

HBA1C level

Time frame:5 months

descriptive

Primary/protocol endpoint

daily glucose level measurement in the blood using Glucometer two to 5 times daily

Time frame:5 months

descriptive

Primary/protocol endpoint

C-Peptide levels in blood in response to Glucose Challenge - Oral Glucose tolerance test ( OGTT ) and Intra venous glucose tolerance test IVGTT

Time frame:5 months

descriptive

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Platelet aggregation to Adenosine diphosphate (ADP) and Collagen - blood test for Platelet function test

Time frame:5 months

descriptive

Primary/protocol endpoint/low confidence

Nerve conduction velocity in VEP

Time frame:5 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.